CERS
Price
$1.35
Change
+$0.05 (+3.85%)
Updated
May 2 closing price
Capitalization
342.62M
89 days until earnings call
INGN
Price
$7.20
Change
+$0.14 (+1.98%)
Updated
May 2 closing price
Capitalization
176.12M
4 days until earnings call
Ad is loading...

CERS vs INGN

Header iconCERS vs INGN Comparison
Open Charts CERS vs INGNBanner chart's image
Cerus
Price$1.35
Change+$0.05 (+3.85%)
Volume$1.48M
Capitalization342.62M
Inogen
Price$7.20
Change+$0.14 (+1.98%)
Volume$124.22K
Capitalization176.12M
CERS vs INGN Comparison Chart
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERS vs. INGN commentary
May 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and INGN is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 03, 2025
Stock price -- (CERS: $1.35 vs. INGN: $7.20)
Brand notoriety: CERS and INGN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 108% vs. INGN: 36%
Market capitalization -- CERS: $342.62M vs. INGN: $176.12M
CERS [@Medical Specialties] is valued at $342.62M. INGN’s [@Medical Specialties] market capitalization is $176.12M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileINGN’s FA Score has 0 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • INGN’s FA Score: 0 green, 5 red.
According to our system of comparison, CERS is a better buy in the long-term than INGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 5 TA indicator(s) are bullish while INGN’s TA Score has 4 bullish TA indicator(s).

  • CERS’s TA Score: 5 bullish, 3 bearish.
  • INGN’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, CERS is a better buy in the short-term than INGN.

Price Growth

CERS (@Medical Specialties) experienced а 0.00% price change this week, while INGN (@Medical Specialties) price change was -1.10% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.26%. For the same industry, the average monthly price growth was -1.11%, and the average quarterly price growth was -1.23%.

Reported Earning Dates

CERS is expected to report earnings on Jul 31, 2025.

INGN is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Medical Specialties (+1.26% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CERS($343M) has a higher market cap than INGN($176M). CERS YTD gains are higher at: -12.338 vs. INGN (-21.483). CERS has higher annual earnings (EBITDA): -26.34M vs. INGN (-58.34M). INGN has more cash in the bank: 128M vs. CERS (65.9M). INGN has less debt than CERS: INGN (21.9M) vs CERS (96M). INGN has higher revenues than CERS: INGN (316M) vs CERS (156M).
CERSINGNCERS / INGN
Capitalization343M176M195%
EBITDA-26.34M-58.34M45%
Gain YTD-12.338-21.48357%
P/E RatioN/A71.43-
Revenue156M316M49%
Total Cash65.9M128M51%
Total Debt96M21.9M438%
FUNDAMENTALS RATINGS
CERS vs INGN: Fundamental Ratings
CERS
INGN
OUTLOOK RATING
1..100
6011
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
82
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9492
PRICE GROWTH RATING
1..100
8263
P/E GROWTH RATING
1..100
10058
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (42) in the Medical Specialties industry is somewhat better than the same rating for INGN (82). This means that CERS’s stock grew somewhat faster than INGN’s over the last 12 months.

CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as INGN (100). This means that CERS’s stock grew similarly to INGN’s over the last 12 months.

INGN's SMR Rating (92) in the Medical Specialties industry is in the same range as CERS (94). This means that INGN’s stock grew similarly to CERS’s over the last 12 months.

INGN's Price Growth Rating (63) in the Medical Specialties industry is in the same range as CERS (82). This means that INGN’s stock grew similarly to CERS’s over the last 12 months.

INGN's P/E Growth Rating (58) in the Medical Specialties industry is somewhat better than the same rating for CERS (100). This means that INGN’s stock grew somewhat faster than CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSINGN
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 23 days ago
77%
Bullish Trend 9 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDCGX83.17N/A
N/A
Fidelity Advisor Consumer Staples C
MNHIX24.76N/A
N/A
Manning & Napier Pro-Blend Max Term I
KAUAX5.43N/A
N/A
Federated Hermes Kaufmann A
DHPYX16.11N/A
N/A
Diamond Hill Mid Cap Y
PBMIX6.98N/A
N/A
Polen US SMID Company Growth Instl

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
+3.85%
LAB - CERS
50%
Loosely correlated
+8.11%
HBIO - CERS
46%
Loosely correlated
+2.23%
NNOX - CERS
45%
Loosely correlated
+3.21%
MXCT - CERS
43%
Loosely correlated
+1.08%
ICUI - CERS
43%
Loosely correlated
+3.41%
More

INGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, INGN has been loosely correlated with VCYT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if INGN jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INGN
1D Price
Change %
INGN100%
+1.98%
VCYT - INGN
47%
Loosely correlated
+2.15%
STRRP - INGN
44%
Loosely correlated
+3.16%
OSUR - INGN
37%
Loosely correlated
+1.36%
ITGR - INGN
36%
Loosely correlated
+0.06%
CERS - INGN
34%
Loosely correlated
+3.85%
More